Upcoming Conferences
June Webinar
Cell Therapy for Solid Cancers:
Promise or Overpromise?
Join us for an insightful session with Dr Sophia Wong, a leading clinician-scientist advancing the future of cellular therapy for solid cancers in Asia.
Trained at leading institutions including University College London Hospital, Royal Free Hospital, the Royal Marsden Hospital, and the Netherlands Cancer Institute, Dr Sophia Wong specialises in translational immunotherapy and innovative T cell therapies for solid tumours. She currently leads pioneering clinical trials at the National Cancer Centre Singapore, including Asia’s first solid cancer cellular TIL therapy trial.
Don’t miss this opportunity to learn from a leading voice at the forefront of next-generation cancer treatment and translational research.
What You Will Learn
Gain valuable insights as Dr Sophia explores:
• The promise vs. reality of cell therapy in solid cancers
• Current challenges and emerging therapeutic approaches
• Expert perspectives shaping the future of cancer immunotherapy
Speaker
Dr. Sophia Wong,
MBBS, MRCP, PhD
SingHealth
Dr Sophia Wong trained as a Medical Oncologist at University College London Hospital and Royal Free Hospital (London), with a PhD in Cancer Immunology from University College London, where she trained under Professor Sergio Quezada. After completing her specialist training in London, she pursued a post-training fellowship in solid cancer cellular therapy at the Royal Marsden Hospital (London) and the Netherlands Cancer Institute. Her clinical and research focus is on translational immunotherapy, particularly in advancing cell therapies for solid tumours.
Dr Sophia started at the National Cancer Centre Singapore in 2024, where she treated and led the first solid cancer cellular TIL therapy trial in Asia. She serves as Principal Investigator for ongoing clinical trials and has been awarded the NMRC Transition Award and STDR Grant to support her research in T cell therapy. Alongside her clinical and academic work, she remains actively involved in teaching and global oncology collaborations, with a goal to expand access to innovative therapies across Asia.
Date: 22 June, 2026 | Monday
Venue: Virtual
July Webinar
Affordable Immunotherapy: Opportunities and Challenges
Join us for an insightful session with Dr. Lim Kue Peng from Cancer Research Malaysia as she explores the future of making cancer immunotherapy more affordable and accessible across Asia.
In her webinar, Dr. Lim will share valuable perspectives on the current landscape of immunotherapy and the need for regionally relevant research to improve cancer care and treatment access.
What You Will Learn
- Explore the opportunities and challenges of making cancer immunotherapy more affordable and accessible.
- Understand key barriers to immunotherapy adoption in Asia
- Explore low-dose immunotherapy trials and understand their opportunities and challenges
- Gain insights into the importance of regionally relevant cancer research in Asia
Speaker
Dr. Lim Kue Peng, PhD
Cancer Research Malaysia
Dr. Lim Kue Peng is a cancer immunology researcher and Head of the Cancer Immunology & Immunotherapy Unit at Cancer Research Malaysia. Her work focuses on developing new cancer treatment approaches, including cancer vaccines designed to train the immune system to target and destroy cancer cells. Through her research, she contributes to advancing more accessible and regionally relevant immunotherapy strategies for patients in Asia.
Date: 24 July 2026 | Friday
Venue: Virtual
August Webinar
On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy in glioblastoma models
Join us for an insightful session with Dr. Keisuke Watanabe, Senior Staff Scientist in the Division of Cancer Immunology at National Cancer Center Japan, as he explores innovative approaches to improving CAR-T cell therapies for solid tumors.
In his webinar, Dr. Watanabe will share insights from his pioneering work in cellular immunotherapy and next-generation CAR-T development. With extensive experience spanning clinical care, translational research, and advanced immunology programs, his research focuses on overcoming key challenges in developing CAR-T therapies for difficult-to-treat cancers.
What You Will Learn
- Metabolic barriers limiting CAR-T cell performance in solid tumors
- The potential of GLUT3 to improve CAR-T cell fitness and persistence
- Novel engineering strategies to enhance antitumor efficacy in glioblastoma models
- Future directions for next-generation CAR-T therapies in non-B-cell malignancies
Speaker
Dr. Keisuke Watanabe
MD, PhD
Senior Staff Scientist, Division of Cancer Immunology, National Cancer Center Japan
Keisuke Watanabe, MD, PhD, is a Senior Staff Scientist in the Division of Cancer Immunology at the National Cancer Center Japan. He had dedicated over a decade to patient care, specializing in hematopoietic stem cell transplantation. Parallel to his clinical practice, he has spearheaded clinical research and translational research (TR) in cell therapy.
In 2015-2019, Dr. Watanabe was a postdoctoral fellow in the laboratory of Dr. Carl H. June at the Center for Cellular Immunotherapies at the University of Pennsylvania. There, he advanced the development of CAR-T cell therapies for T-cell malignancies and solid tumors, including combinatorial approaches with oncolytic viruses.
Since joining the National Cancer Center Japan in 2019, Dr. Watanabe has led various immunology programs. His current research focuses on developing CAR-T cells for non-B-cell malignancies, with a particular emphasis on AI-designed CARs to address the tonic signaling, CARs for T-cell tumors, and strategies to overcome metabolic checkpoints in the tumor microenvironment.
Date: 21 August 2026 | Friday
Venue: Virtual
WIC-APAC 2026
The 2026 World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026), hosted in conjunction with the TSITC Annual Meeting and the TOS Spring Summit, brings together leading experts and the broader cancer immunotherapy community to share cutting-edge science, strengthen regional collaboration, and advance patient care across APAC.
Why Attend WIC-APAC 2026?
A regional gathering advancing cancer immunotherapy science, care, and collaboration across the Asia-Pacific.
Date: 28 – 29 March, 2026 | Sat – Sun
Venue: Taipei, Taiwan | Chang Yung-Fa Foundation (CYFF) International Convention Center
Visit Conference website: https://wicapac2026.org/
Conference Highlights
Scientific Program & Keynote sessions
Cross-disciplinary Collaboration
Early-Career & Young Investigator Opportunities
Networking & Community
Built on a Strong previous edition (WIC-APAC 2025)
Global Turnout
Around 200 participants
from 17+ countries
100% Top-Rated
Scientific content and speakers / faculty quality were rated excellent or good by all respondents
100% Recommend
100% of respondents would recommend this WIC-APAC to colleagues
90%+ Skills Boost
Over 90% reported increased professional competencies following the conference
International Surgical Oncology Symposium (ISOS 2026)
ISOS 2026 is a premier event dedicated to advancing the field of surgical oncology through education, collaboration, and innovation. This one-day symposium will strengthen the pipeline from discovery to bedside by integrating cutting-edge research, and clinical expertise.
29 August, 2026 | NUHS Auditorium | Singapore
Objectives:
1: Advance the field of peri-operative immunotherapy through education, collaboration and innovation.
2: Strengthen the surgical oncology pipeline from discovery to bedside, bridging research and clinical practice.
3: Integrate cutting-edge research with clinical expertise.
4: Foster collaboration among clinicians, researchers and innovators.
Contact Us:
- Braudon Yeo | Manager
- Direct: +65-6994-5464 or Office: +65 – 6994-5461 # 298
AP-SciBio2027 x WIC APAC 2027
AP-SciBio2027 × WIC-APAC2027 unite spatial biology and immunotherapy into a single, powerful platform.
Through international collaboration across the Asia-Pacific region, this joint meeting bridges high-resolution cellular and tissue maps with the real-world delivery of life-saving immunotherapies.
As part of the PEACE Symposia Pacific Series, the meeting convenes global leaders from academia, clinics, and industry to explore AI-decoded insights in tissue architecture, cellular ecosystems, and multi-omics—shaping the next era of precision science and medicine across the region and beyond.
25 – 27 February, 2027 | Bangkok, Thailand